Rigel Pharmaceuticals (RIGL) FCF Margin (2010 - 2026)

Rigel Pharmaceuticals' FCF Margin history runs 16 years deep, the most recent figure standing at 4.63% for Q1 2026.

• In Q1 2026, FCF Margin rose 631.0% year-over-year to 4.63%; the TTM figure through Mar 2026 stood at 26.44% (up 892.0% YoY), while the FY2025 annual figure was 25.71%, up 815.0% from the prior year.
• FCF Margin for Q1 2026 stood at 4.63%, down from 31.49% in the prior quarter.
• The five-year high for FCF Margin was 39.2% in Q3 2024, with the low at 154.53% in Q1 2022.
• The 5-year median for FCF Margin is 1.67% (2025), against an average of 9.82%.
• The sharpest annual moves came in 2022 and 2023: FCF Margin tumbled 25155 bps in 2022, then jumped 13928 bps in 2023.
• Rigel Pharmaceuticals' FCF Margin stood at 44.56% in 2022, then soared by 61 bps to 17.52% in 2023, then surged by 244 bps to 25.18% in 2024, then climbed by 25 bps to 31.49% in 2025, then slumped by 85 bps to 4.63% in 2026.
• Business Quant data shows RIGL's FCF Margin at 4.63% in Q1 2026, 31.49% in Q4 2025, and 34.6% in Q3 2025.